Author

S. Michael

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Biochemistry· 2 Cell Biology· 2 Microbiology· 2 Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:drug response / drug discovery· 5 Research Focus:cell type annotation· 4 Organism:human· 4 Assay:proteomics· 4 Assay:bulk RNA-seq· 3 Research Focus:clustering· 3 Research Focus:differential expression· 3

Frequent Co-Authors

A. Simeonov· 9 shared C. Klumpp-Thomas· 6 shared W. Zheng· 5 shared M. Xu· 4 shared Z. Itkin· 4 shared A. V. Zakharov· 3 shared C. Z. Chen· 3 shared H. Guo· 3 shared

Activity by Year

2019-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersPharmacology & Toxicology

A. Simeonov

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Selective refueling of CAR T cells using ADA1 and 1 CD26 boosts antitumor immunity

Y. Hu, A. Sarkar, K. Song, S. Michael, M. Hook, R. Wang, A. Heczey, X. Song

This study shows that engineering CAR T cells to co-express ADA1 and CD26 improves their antitumor activity by selectively refueling them with inosine in the tumor microenvironment.

bioRxiv · Sep 18, 2023Immunology

Locus specific human endogenous retroviruses reveal new lymphoma subtypes

B. Singh, N. Dopkins, T. Fei, J. L. Marston, S. Michael, H. Reyes-Gopar, G. Curty, J. J. Heymann, A. Chadburn, P. Martin, F. E. Leal, E. Cesarman, D. F. Nixon, M. L. Bendall

The paper identifies unique HERV signatures in B-cell lymphoma subtypes that can improve classification and diagnosis when combined with gene expression.

bioRxiv · Jun 8, 2023Cancer Biology

A real-time cellular thermal shift assay (RT-CETSA) to monitor target engagement

T. W. Sanchez, M. H. Ronzetti, A. E. Owens, M. Antony, T. Voss, E. Wallgren, D. Talley, K. Balakrishnan, G. Rai, J. J. Marugan, S. Michael, B. Baljinnyam, N. Southall, A. Simeonov, M. J. Henderson

The paper introduces RT-CETSA, a real-time cellular thermal shift assay that improves throughput and sensitivity for monitoring ligand-target engagement in cells.

bioRxiv · Jan 24, 2022 · PreprintPharmacology & Toxicology

A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry

M. Xu, M. Pradhan, K. Gorshkov, J. D. Petersen, M. Shen, H. Guo, W. Zhu, C. Klumpp-Thomas, S. Michael, M. Itkin, Z. Itkin, M. R. Straus, J. Zimmerberg, W. Zheng, G. Whittaker, C. Z. Chen

This paper develops a high throughput screening assay using SARS-CoV-2 pseudotyped particles to identify inhibitors of viral entry, finding 7 active compounds effective against both pseudotyped particles and live virus.

bioRxiv · Oct 4, 2021Pharmacology & Toxicology

Cross-platform Bayesian optimization system for autonomous biological assay development

S. Elder, C. Klumpp-Thomas, A. Yasgar, J. Travers, S. Frebert, K. M. Wilson, A. V. Zakharov, J. L. Dahlin, C. Kreisbeck, D. Sheberla, G. S. Sittampalam, A. G. Godfrey, A. Simeonov, S. Michael

This paper develops a cross-platform Bayesian optimization system to accelerate biological assay development, reducing costs and time compared to brute force methods.

bioRxiv · Jun 23, 2021Biochemistry

Robotic High-Throughput Biomanufacturing and Functional Differentiation of Human Pluripotent Stem Cells

C. A. Tristan, P. Ormanoglu, J. Slamecka, C. Malley, P.-H. Chu, V. M. Jovanovic, Y. Gedik, C. Bonney, E. Barnaeva, J. Braisted, S. K. Mallanna, D. Dorjsuren, M. J. Iannotti, T. C. Voss, S. Michael, , I. Singec

This paper develops a robotic platform for high-throughput manufacturing and differentiation of human pluripotent stem cells, validated through molecular and functional analyses.

bioRxiv · Aug 3, 2020Bioengineering

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro

T. Bobrowski, L. Chen, R. T. Eastman, Z. Itkin, P. Shinn, C. Chen, H. Guo, W. Zheng, S. Michael, A. Simeonov, M. Hall, A. V. Zakharov, E. N. Muratov

This study identifies synergistic and antagonistic drug combinations against SARS-CoV-2 in vitro using in silico prioritization and experimental testing.

bioRxiv · Jun 29, 2020Microbiology

Real-time sharing of drug screening data on the NCATS OpenData Portal accelerates translational research

K. R. Brimacombe, P. C. Scully, T. Zhao, R. T. Eastman, X. Hu, K. Wang, M. Backus, B. Baljinnyam, C. Z. Chen, L. Chen, Y. Cheng, D. P. Davis, K. Duerr, T. Eicher, A. Friedman, , M. D. Hall

This paper describes the NCATS OpenData Portal, a platform for real-time sharing of drug screening data that accelerates translational research by enabling immediate access to large-scale datasets.

bioRxiv · Jun 4, 2020 · PreprintBiochemistry

The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators

K. Gorshkov, C. Z. Chen, R. Bostwick, L. Rasmussen, M. Xu, M. Pradhan, B. N. Tran, W. Zhu, K. Shamim, W. Huang, X. Hu, M. Shen, C. Klumpp-Thomas, Z. Itkin, P. Shinn, , W. Zheng

The paper identifies six autophagy modulators that block SARS-CoV-2 cytopathic effects in Vero-E6 cells with EC50 values between 2.0 and 13 µM.

bioRxiv · May 16, 2020Pharmacology & Toxicology

An Integrated Systems Biology Approach Identifies the Proteasome as a Critical Host Machinery for ZIKV and DENV Replication

G. Song, E. M. Lee, J. Pan, M. Xu, H.-S. Rho, Y. Cheng, N. Whitt, S. Yang, J. Kouznetsova, C. Klumpp-Thomas, S. Michael, C. Moore, K.-J. Yoon, K. Christian, A. Simeonov, , H. Zhu

The paper identifies the proteasome as critical for ZIKV and DENV replication through three systems biology approaches and finds proteasome inhibitors suppress both viruses.

bioRxiv · Mar 4, 2020Microbiology

A Versatile Polypharmacology Platform Promotes Cytoprotection and Viability of Human Pluripotent and Differentiated Cells

Y. Chen, C. A. Tristan, L. Chen, V. Jovanovic, C. Malley, P.-H. Chu, S. Ryu, T. Deng, P. Ormanoglu, D. Tao, Y. Fang, J. Slamecka, C. A. LeClair, S. Michael, C. P. Austin, , I. Singec

The paper identifies a small molecule cocktail, CEPT, that enhances the viability and cytoprotection of human pluripotent and differentiated cells through multi-target drug combinations.

bioRxiv · Oct 22, 2019Cell Biology

Keeping it clean: the cell culture quality control experience at the National Center for Advancing Translational Sciences

J. S. Roth, T. D. Lee, D. M. Cheff, M. L. Gosztyla, R. Asawa, C. Danchik, S. Michael, A. Simeonov, C. Klumpp-Thomas, K. Wilson, M. D. Hall

The paper describes NCATS's implementation of mycoplasma and STR testing to improve cell line quality, reducing contamination and misidentification in translational research.

bioRxiv · Oct 9, 2019Cell Biology